European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - epoetin zeta - anemia; blood transfusion, autologous; kidney failure, chronic; cancer - other antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males).retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. use should be restricted to patients with moderate anaemia (e.g. hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml).

European Union - English - EMA (European Medicines Agency)

stada arzneimittel ag - epoetin zeta - anemia; blood transfusion, autologous; cancer; kidney failure, chronic - antianemic preparations - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patientstreatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis.treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre‑existing anaemia at the start of chemotherapy).silapo can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).silapo is indicated for non-iron deficient adults prior to major elective orthopaedic surgery having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. use should be restricted to patients with moderate anaemia (e.g. haemoglobin concentration range between 10 to 13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1 800 ml).silapo can be used to increase haemoglobin concentration in symptomatic anaemia (haemoglobin concentration of ≤10 g/dl) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (mds) who have low serum erythropoietin (

Australia - English - Department of Health (Therapeutic Goods Administration)

getinge australia pty ltd - 35071 - filter, blood transfusion - a filter designed for use in an extracorporeal circulation system to remove particulate and gaseous micro-embolisms.

United States - English - NLM (National Library of Medicine)

ssm cardinal glennon children's medical center st. louis cord blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 35 ml - allocord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none pregnancy category c. animal reproduction studies have not been conducted with allocord. it is also not known whether allocord can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st

United States - English - NLM (National Library of Medicine)

new york blood center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 25 ml - hemacord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none pregnancy category c. animal reproduction studies have not been conducted with hemacord. it is also not known whether hemacord can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st

United States - English - NLM (National Library of Medicine)

lifesouth community blood centers, inc. - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 25 ml - cordcyte, hpc (hematopoietic progenitor cell), cord blood is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. pregnancy category c. animal reproduction studies have not been conducted with cordcyte. it is also not known whether cordcyte can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st

United States - English - NLM (National Library of Medicine)

duke university school of medicine, carolinas cord blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 900000000 in 25 ml - ducord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. risk summary there are no data with ducord use in pregnant women to inform a product-associated risk. animal reproduction studies have not been conducted with ducord. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in

United States - English - NLM (National Library of Medicine)

cleveland cord blood center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 25 ml - clevecord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. risk summary there are no data with clevecord use in pregnant women to inform a product-associated risk.  animal reproduction studies have not been conducted with clevecord. in the u.s. general population, the estimated background risk of major birth defects and misca

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium chloride, quantity: 9 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 01 jan 1991 : prophylaxis of heat prostration or muscle cramps, chloride deficiency due to diuresis or salt restriction, prevention or treatment of extracellular volume depletion. parenteral - 0.9% (isotonic) nacl is used to restore sodium and chloride losses; to dilute or dissolve drugs for iv, im or sc use, flushing of iv catheters; extracellular fluid replacement; priming solution for hemodialysis; initiate and terminate blood transfusions so red blood cells will not hemolyze; metabolic alkalosis when there is fluid loss and mild sodium depletion. topical or irrigation - relief of inflamed, dry or crusted nasal membranes or as a topical irrigating or flush solution.

Australia - English - Department of Health (Therapeutic Goods Administration)

terumo bct australia pty ltd - 44037 - blood donor set, triple-pack - blood bags are sterile plastic collapsible containers for single use only, and used for collection, processing, storage and transfusion of whole blood or blood components